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visual disturbances, epigastric pain, vomiting) (C), 
and clinical suspicion of fetal compromise (B)
• Measure blood pressure with equipment 
that is accurate in individual hypertensive 
pregnant women (C). Use appropriate cuff size 
(C)—thigh cuffs (18×36 cm) for women with an 
arm circumference of 41 cm or more. Follow 
PRECOG recommendation 6 for reducing errors 
in blood pressure measurement6 (C, D, GPP)
• Estimate proteinuria by dipsticks (C) and 
follow PRECOG recommendation 7 to 
improve reliability.6 Accuracy is not increased 
by retesting a new sample (GPP). Use 
the higher of the dipstick results from the 
community and the day assessment unit (GPP)
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Why read this summary?
Pre-eclampsia remains a leading cause of maternal 
death, with 72% of pre-eclampsia cases associated with 
substandard care.1 One in 10 pregnant women develop 
partial signs or symptoms (73 000 a year in the United 
Kingdom); about 20% of these progress to pre-eclamp-
sia.2 3 This article summarises recommendations from 
the Pre-Eclampsia Community Guideline (PRECOG) 
Group4 under the auspices of the charity Action on Pre-
eclampsia. The recommendations cover the assessment 
of women with suspected pre-eclampsia by hospital 
midwives in day assessment units and complements 
our previous community based advice.5 6
Recommendations
PRECOG recommendations (see table 1 for definitions 
used) are based on systematic review of evidence and 
expert consensus, graded A, B, C, or D; a “good prac-
tice point”(GPP) is based on the guideline development 
group’s experience (box 1 on bmj.com). The grading is 
shown in parentheses after each recommendation. 
Midwives in a day assessment unit should offer 
women the following step-wise investigations and 
management.
Step 1
For all referrals for suspected pre-eclampsia
• Take a history, including checking for PRECOG 
risk factors for pre-eclampsia (table 2) (B/C)
• Confirm the presence of any one of new 
hypertension (B), new proteinuria (B), maternal 
symptoms of pre-eclampsia (such as headache, 
Table 1 | Definitions used in the PRECOG recommendations 
Term Definition used in guideline
Fetal compromise (clinical 
suspicion)
Reduced fetal movements, small for gestational age infant (clinically assessed)
Hypertension A diastolic blood pressure of ≥90 mm Hg 
New hypertension Hypertension at or after 20 weeks’ gestation in a woman with a diastolic blood pressure of <90 mm Hg before 20 weeks
Pre-existing hypertension A diastolic blood pressure before pregnancy or at booking (before 20 weeks) of ≥90 mm Hg
New proteinuria The presence of proteinuria as shown by 1+ (0.3 g/l) or higher on dipstick testing; a protein to creatinine ratio of ≥30 on 
a random sample; or a urine protein excretion of ≥300 mg/24 h
Significant proteinuria Urine protein excretion ≥300 mg/24 h
Pre-eclampsia New hypertension and significant proteinuria at or after 20 weeks of pregnancy, confirmed if it resolves after delivery
Superimposed pre-eclampsia The development of features of pre-eclampsia in the context of pre-existing hypertension, pre-existing proteinuria, or both
Table 2  | Factors that can be measured early in pregnancy that 
increase the likelihood of pre-eclampsia in any given pregnancy6
Factor PRECOG grade
First pregnancy B
Multiparous:
 Pre-eclampsia in any previous pregnancy B
 ≥10 years since last baby B
Age ≥40 years B
Body mass index of ≥35 B
Family history of pre-eclampsia (mother or sister) B
Diastolic blood pressure of ≥80 mm Hg at booking B
Proteinuria (of ≥1+ on more than one occasion or 
quantified at ≥0.3 g/24 h) at booking
C
Multiple pregnancy B
Certain underlying medical conditions* B
*Pre-existing hypertension; pre-existing renal disease; pre-existing 
diabetes; antiphospholipid antibodies present.
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 Step 2
For suspicion of fetal compromise and/or maternal symptoms
• Follow local protocols.
For new hypertension (no maternal symptoms or fetal  
compromise)
• Admit women with a diastolic blood pressure   
≥110 mm Hg or systolic blood pressure ≥170 mm 
Hg (D).
• Arrange a medical review to consider admission for 
women with a diastolic blood pressure 100-109 mm 
Hg or systolic blood pressure 160-169 mm Hg (D).
• Measure the platelet count, liver function (aspartate 
aminotransferase or alanine aminotransferase), and 
serum creatinine for women with a diastolic blood 
pressure 90-99 mm Hg. Do not test for serum 
urate if proteinuria is not present. Use pregnancy 
specific ranges (box, table 3) (C); do not use results 
to predict subsequent pre-eclampsia (C). Use 
results to identify features of HELLP syndrome 
(name derived from its features: Haemolysis, 
Elevated Liver enzymes, and Low Platelet count) 
and underlying concurrent conditions, and as 
a baseline to determine rate of change and also 
appropriate management if pre-eclampsia develops 
(GPP).
• Arrange a Doppler scan of the umbilical artery to 
assess fetal risk if onset of new hypertension is ≤36 
completed weeks (B).
Once the test results are available, do the following:
• Arrange medical review of abnormal blood test 
results or umbilical artery Doppler readings (GPP)
• Repeat step 1 assessments in one week if blood test 
results are normal; do not routinely repeat blood 
tests unless signs or symptoms change or routine 
repeat testing is recommended after medical review 
(D/GPP)
• Discuss the results and the plan for antenatal care 
with the woman (GPP). 
For new proteinuria (no maternal symptoms or fetal 
co mpromise)
For 2+ proteinuria, do the following:
• Measure the platelet count; aspartate 
aminotransferase or alanine aminotransferase; serum 
creatinine; and serum urate (C). Use abnormal 
results for pregnancy specific ranges to diagnose 
partial HELLP syndrome, indicate underlying 
concurrent conditions, predict risk of poor maternal 
and/or fetal outcome, and establish a baseline for 
monitoring disease progression and predicting 
morbidity if pre-eclampsia does develop (C/D)
• Arrange a 24 hour urine collection to quantify 
proteinuria (C)
• Arrange a Doppler scan of the umbilical artery 
to assess fetal risk if proteinuria onset is ≤36 
completed weeks (C)
• Arrange a medical review of abnormal or 
significant results (GPP).
For 1+ proteinuria, do the following:
• Exclude significant proteinuria by calculating the 
urinary protein to creatinine ratio from a random 
sample (C) or confirm and quantify by 24 hour 
urine collection (C). Use a threshold ratio of 30 to 
exclude significant proteinuria.14
For new hypertension and proteinuria
• Admit women with a diastolic blood pressure of 
≥90 mm Hg and new proteinuria of ≥2+. (C)
• Admit women with a diastolic blood pressure of 
≥110 and new proteinuria of ≥1+. (C)
• Arrange a medical review to consider admission of 
women with a diastolic blood pressure of 100-109 
mm Hg and new proteinuria of 1+ (C)
• For women with diastolic blood pressure of 90-99 
mm Hg and 1+ proteinuria, exclude significant 
proteinuria using the urinary protein creatinine 
ratio from a random sample (C) or confirm and 
quantify by 24 hour urine collection. (C)
Once the test results are available, do the following:
• Admit if significant proteinuria is confirmed 
or the protein creatinine ratio is ≥30 with new 
hypertension (C)
• Arrange a medical review of abnormal blood test 
results or Doppler readings. Discuss the results and 
the plan for antenatal care with the women. (GPP)
For transient new hypertension or new proteinuria
• Recheck women with no hypertension or 
proteinuria (after step 1) in the community within 
Table 3 | Pregnancy specific ranges (calculated from 2 standard 
deviations above and below mean values) for serum uric acid by 
gestational age (μmol/l)10
Gestational age Range
Not  pregnant 128-364
At 4 weeks 152-328
At 8 weeks 50-330
At 12 weeks 79-267
At 16 weeks 93-285
At 24 weeks 116-276
At 32 weeks 110-322
At 36 weeks 120-344
At 38 weeks 157-381
Post-partum 161-389
Liver function (gestation specific values, 95% reference 
ranges (2.5th centile to  97.5th centile)) in normal 
population11 and platelet count12 and creatinine 
concentration13 (pregnancy specific measures)
Liver function tests*
Aspartate aminotransferase (IU/l)
Non-pregnancy: 7-40
1st trimester: 10-28
2nd trimester: 11-29
3rd trimester: 11-30
Alanine aminotransferase (IU/l)
Non-pregnancy: 0-40
1st trimester: 6-32
2nd trimester: 6-32
3rd trimester: 6-32
Pregnancy specific measures for platelet count and 
creatinine 
Platelet count: ≥150× 109/l
Creatinine: ≤90 μmol/l
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seven days. Women in this category are at higher 
risk of developing pre-eclampsia (51% subsequently 
develop hypertension or pre-eclampsia in the 
pregnancy).15 Refer back to the day assessment 
unit if signs or symptoms recur with community 
monitoring (PRECOG recommendations 4 and 5).6
Minimum standards
We recommend minimum standards for facilities and 
staff in any consultant led, hospital based day assessment 
unit,4 especially the following standards:
• Medical review requires specialty registrar ST3 or 
above (GPP)
• Allocate all women referred for further assessment 
to a named consultant (GPP)
• Offer written and verbal information so that 
women understand the purpose and outcome of 
the assessment at the day assessment unit. Women 
have a full and equal right to determine and be 
involved in their antenatal care. (GPP)
Overcoming barriers
Over 90% of day assessment units share staff with ante-
natal and labour wards and often have lower priority for 
staff.9 However, their remits have enlarged to include 
triage, management of labour, post-maturity assessment, 
and postnatal assessment. The pre-eclampsia assess-
ments vary across these units, and equipment is often 
inadequate or poorly maintained.9 Errors have been 
implicated in maternal deaths.16 Minimum standards 
are essential for a cost effective service from day assess-
ment units. Standardising assessments will be cost saving 
and preferred by women when unnecessary admission is 
avoided.17 Adoption, training, and implementation sup-
port is available via www.apec.org.uk. 
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Are the medical schools of Great Britain to be disgraced by 
 demoralising spectacles such as I have seen in Paris in connection with 
the education of female medical students? I have seen in M. Fort’s 
rooms a young woman dissecting the thigh of a male subject while 
several male students were dissecting other parts of the same body. I 
have seen another young woman, with unblushing front, taking notes 
along with young men, her fellow-students, of a lecture by Professor 
Pajot exclusively devoted to the mons Veneris, clitoris, and hymen, 
illustrated by curious anecdotes and preparations. These disgusting 
spectacles made a strong impression upon my mind; and I was glad 
to be able to show to inquiring friends recent articles in the BRITISH 
MEDICAL JOURNAL as proofs that notwithstanding the statements 
of La Liberté and other Parisian prints, purity is in our country, as it 
ever has been, the cherished ideal of w omanhood, and that such sights 
as I have now described would be there regarded as too horribly 
revolting to be tolerated. 
No doubt, if women are to have a fair chance of being equal to men 
as physicians and surgeons, they must learn their profession along with 
and in the same way as men. But then, are women-doctors required? 
Is it not rather a certainty that men are physically better adapted than 
women for medical practice, and that men-doctors will in ninety-nine 
cases in a hundred successfully compete with women-doctors ? Is it not 
cruel, therefore, to women and injurious to men to allure women to 
barter modesty for medicine? 
Women-doctors: Parisian socialists, and Edinburgh professors. BMJ 1870;1:559-60, doi:10.1136/
bmj.1.491.558
The entire archive of the BMJ, going back to 1840, is now available at www.bmj.com/archive.
Cite this as: BMJ 2009;339:b2251
FROm OuR ARChIvE  Women doctors (1870)
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A PATIEnT’s JOuRnEy 
Persistent pain
Mary Ray, Joan Hester
UsEFUL REsOURCEs 
British Pain Society (www.britishpainsociety.org.uk)—A 
multiprofessional organisation advancing the understanding 
and management of pain. Churchill House, 35 Red Lion 
Square, London WC1R 4SG
Chronic Pain Policy Coalition (www.paincoalition.org.uk/
index.htm)—Organisation working to improve the lives of 
people who live with chronic pain
Chief Medical Officer. Pain: breaking through the barrier. In: 
Chief Medical Officer 2008 Annual Report. www.dh.gov.uk/
en/Publicationsandstatistics/Publications/AnnualReports/
DH_096233
Healthtalkonline (www.healthtalkonline.org)—Charity 
website specialising in patients’ stories and experiences
Youthhealthtalk (www.youthhealthtalk.org)— Charity website 
specialising in young patients’ stories and experiences
Pancreatitis Supporters’ Network (www.pancreatitis.org.uk)— 
Voluntary group providing information, support, and 
networking for people with pancreatitis
Chronic pancreatitis (www.creoninfo.co.uk/pdf/Booklet1.
pdf)—Leaflet about pancreatitis and its treatments, by J P 
Neoptolemos, professor of surgery at University of Liverpool 
Expert Patient Programme (www.expertpatients.co.uk)—NHS 
supported programme, led by lay people, for people who live 
with long term conditions.
This patient describes the strategies she has developed for coping with her persistent pain 
from longstanding pancreatitis
lowing months acceptance and coping got harder as I 
was assessed for whether a pancreatectomy might stop 
the pain. I saw three consultants (in gastroenterology, 
diabetes, and pancreatic surgery), who outlined the ben-
efits and risks. It wasn’t the right answer for me but it 
highlights a common dilemma: a chance to be free of 
pain sets you hoping and decisions about major intru-
sive procedures become an emotional roller coaster.
Referral to a pain clinic
I’m a psychologist so I was already using ways of man-
aging pain: relaxation, goal setting, staying positive. I 
was referred to a pain clinic to see if I could improve 
what I was already doing. This was about 10 years ago 
and services have moved on, but there are still lessons to 
be learnt even now, and the learning process is continu-
ous. Every patient had months of waiting to see a pain 
consultant, before being referred via another waiting list 
to see a psychologist, then a third wait for group sessions 
to learn a few basic ways to manage pain. Three waiting 
lists before learning useful strategies such as relaxation 
and positive thinking.
It didn’t make sense. Why wait so long to talk to 
people about understanding pain and simple ways to 
cope with it? All that time for a downward spiral with 
patients off work, with bouts of depression, repeated 
clinic attendance, increased use and side effects of pain-
killers, frustration with NHS staff, and ultimately refer-
ral to an intensive pain management programme.
Coping with persistent pain effectively depends on 
patients understanding and managing their pain. And 
they need to begin at the start of their “patient jour-
ney” not at the end. People need a positive message: 
you can make a huge difference yourself and here are 
some of the ways you can do it. Ways of managing pain 
can be easily taught using everyday language. If people 
don’t need simple pointers about relaxation or pacing—
because they improve or there’s an effective treatment—
nothing is wasted. But meanwhile, it can open people’s 
minds, help prevent that downward spiral, and set posi-
tive habits for later if that proves necessary. And offering 
ways to manage pain early is cost effective because it 
minimises the personal and economic costs of long term 
disability, unemployment, or mental health problems.
Pain management is a kind of curriculum: under-
standing pain; acceptance and positive thinking; relaxa-
tion and managing stress; pacing; managing medication; 
and safe ways to stay active. To improve access and 
reduce costs, the pain management advice can be deliv-
ered by nurses and physiotherapists in either primary 
or secondary care, with some input from past patients 
In his annual report, published in March this year, 
 Professor Sir Liam Donaldson, the UK government’s 
principal medical adviser, noted that almost eight million 
Britons have persistent chronic pain, which can prevent 
them working and ruin the quality of their lives. And yet, 
he said, because the UK has only one pain management 
specialist for every 250 000 citizens, only one in seven 
people with persistent pain ever sees a specialist.
I’ve had chronic pancreatitis for over 12 years. I 
wasn’t your typical pancreatitis patient: I wasn’t male 
or in my 70s, and I hadn’t misused alcohol. I’m one of 
a third of people for whom the cause is unknown. Quite 
simply, it’s a pig: persistent pain, tiredness, and frequent 
diarrhoea. And it disrupts your life. I kept working for 
over two years, but I was going downhill rapidly and I 
reluctantly had to take early retirement.
Part of coping with persistent pain is to give it as 
little airtime as possible: talking about it doesn’t win 
friends and influence people. So it’s strange to be 
w riting this, but it’s a chance to raise the profile of 
persistent pain and pain management.
diagnosis
I was told the pain would probably be with me for ever 
when the pancreatitis was diagnosed after months of 
tests. I was already learning to live with it. Over the fol-
PRACTICE
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Chronic pancreatitis is an unusual and unpleasant cause of persistent pain. It is described with 
difficulty, often as pain that is diffuse, deep inside the abdomen, and in the back. It is often 
worse on lying down so that sleep is interrupted. Combined with diarrhoea and constant fatigue 
it is easy to understand how a patient could become desperate and might plead to have the 
pancreas removed to abolish the pain. Healthcare professionals often assume that the patient 
has been an alcoholic and adopt a hardening attitude.
Our understanding of the mechanisms of persistent visceral pain is advancing rapidly. 
Acute pancreatitis is known to release inflammatory mediators that stimulate autonomic C 
fibres, transmitting a barrage of nociceptive input to the dorsal horn of the spinal cord, which 
responds by becoming more receptive to pain inputs, a phenomenon known as “wind-up” or 
central sensitisation. Previously silent NMDA (N-methyl-D-aspartate) receptors become active, 
and impulses are sent via the dorsal columns to the limbic system and higher centres of the 
brain. Descending facilitatory pathways from the rostral area of the brain are activated early 
in the process, and this may increase the perception of pain even further. For reasons that are 
less clear these pain pathways do not always revert to their “normal” state when the acute 
episode is over. Persistent pain may be related to the severity of the original illness, to ongoing 
sensitisation by inflammatory mediators, to altered immune responses, and to genetic factors.
As with amputation of a limb, removal of the pancreas will not remove these secondary 
changes in pain signalling mechanisms, and will not abolish the pain of chronic pancreatitis. 
For similar reasons, coeliac plexus block, successful in treating pain from pancreatic cancer, is 
not helpful for pain from chronic pancreatitis.
The pain from chronic pancreatitis is usually responsive to strong opioids and may also 
respond to agents used to treat neuropathic pain, such as gabapentin and amitriptyline. Strong 
opioids, morphine, oxycodone, fentanyl and buprenorphine have to be titrated to response 
and the dose closely monitored, preferably by a pain specialist. Apart from chronic constipation 
long term opioids are known to suppress the hypothalamic-pituitary axis, leading to loss of 
libido, altered sexual function, and in some cases suppression of cortisol levels. However, 
when used wisely, opioids can improve quality of life and activity levels.
Mary highlights the need for a patient with chronic pain to develop coping strategies and 
a sound understanding of why the pain is persistent and why it cannot be cured. She is very 
receptive to the principles of pain management and has applied them in a remarkable way. She 
has also managed to remain optimistic and leads a fulfilling, albeit different, life. Other patients 
take longer to do this; some never achieve this acceptance and continue to search for a cure.
Joan Hester, consultant in pain medicine
POssiBLE BARRiERs TO EFFECTivE PAin MAnAGEMEnT
Several factors may limit the effectiveness of pain management. These may be to do 
with the patient or the way services are offered. Every patient is different, with different 
views and approaches, but it’s worth thinking of ways to minimise possible barriers. The 
following are not exhaustive or in any priority order.
Patient barriers
Resistance to change •	
Generally pessimistic view of life•	
First language other than English •	
Income problems and/or “benefit trap” (where someone receives more income from •	
benefits than they would from employment)  
Strong expectation of a “cure” for pain •	
Disability other than the disability caused by the pain•	
Limited availability for pain management sessions—in terms of time, place, transport, •	
and costs
Health service barriers*
Pain management sessions at the end of a patient journey rather than the start•	
Long wait between the diagnosis of the medical condition causing the pain and the •	
referral for pain management
Long wait for the first “pain” appointment•	
Medical model rather than patient partnership model•	
Pain assessment tools administered by clinicians rather than the provision of tools for •	
self assessment
Jargon—for example, “psychological techniques” rather than “ways to manage pain”•	
Lack of follow-up•	
*The Department of Health’s new “18 week referral pathway” for pain management 
(www.18weeks.nhs.uk) should help to minimise these barriers
who are managing their pain effectively. Health visi-
tors and nurses already support people with long term 
conditions; they can be at the heart of delivering pain 
management.
It may be better to offer ways to manage pain without 
the psychology label. People can sometimes react to the 
word “psychology” with resistance or distrust or be con-
cerned that they may be seen as having a mental health 
problem rather than physical pain. They may feel more 
open to self help in nurse led or patient led groups than 
to a consultation with a psychologist, and they may be 
happy also to see physiotherapists for advice on safe 
exercise. Psychologists could then train facilitators and 
see patients with more intractable problems.
A patient centred approach doesn’t undermine the 
clinical route. Diagnosis is still crucial, and specific treat-
ments can still make a difference. But working in partner-
ship right from the start with patients who take control 
of their own care makes things easier for clinical staff 
too. Then by the time a patient sees a pain consultant 
he or she will be informed and involved and may have 
more realistic expectations—especially if a “cure” may 
not be possible.
Things that help
As a patient
Lots of things make a difference to coping with persist-
ent pain: relationships, personality, attitude to change, 
staying active and involved, income, and realistic expec-
tations. I see it as a kind of luck that I’m a determined 
person as it helps me stay positive and build things into 
my life that I used to get from work: a sense of purpose 
and belonging; making a contribution; contact with like 
minded people. My income is dramatically reduced but 
we can manage. And my partner, Tony, has been there 
with the difficult job of being alongside me, being kind, 
and not fussing when underneath he’s worried.
Persistent pain does disrupt your life. Living with pain 
will be a whole lot harder if you’re on your own or in a 
strained relationship; if you’re naturally pessimistic and 
resistant to change; if you lose your job or are trapped 
between benefits and low paid part time work; or if you 
expect a magic cure.
Doing things you love is important. I’ve always loved 
to dance and it lifts my spirits so much that the hike in 
pain is worth it, with a good rest afterwards to recover. 
And letting go helps, too. So I sometimes give in and 
have a private cry when the “never-endingness” of the 
pain needs an outlet, before I pick myself up and start 
again.
As clinicians
I have good general practitioners and a good consult-
ant. They listen. They give clear, full answers to my 
questions and they’re open when they’re thinking 
things through or aren’t sure about something. That’s 
incredibly important for trust. It’s helpful to hear their 
active problem solving. It’s honest and helps me to be 
realistic when there really isn’t an answer. And it makes 
it feel like a shared journey, rather than being the object 
of their unspoken thoughts.
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Doctors can make a difference when symptoms 
change. It’s difficult to know whether changes are part 
of the ongoing problem or might signal something 
else. There’s a danger of becoming scared of “what 
might happen” and stopping doing things, so I’ve had 
to learn to balance staying active and being sensible. I 
hate making a fuss and don’t want to live with constant 
attention to how I feel, so continuity and support from 
doctors who know you is crucial. It can be difficult for 
doctors too when little can be done medically to change 
the impact of persistent pain.
But more than anything else, the biggest difference 
that clinicians and managers can make is to ensure that 
patients learn ways to cope with their pain as early as 
possible. There’s no such thing as a typical patient. And 
yet we all need to understand our pain and learn how to 
cope with it. If we can learn to do that effectively, as early 
as possible, it helps clinicians too. The worst thing—for 
the patient and their family, for clinicians, for the health 
service, and for the economy—is to leave pain to create 
a downward spiral.
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Ordinary camera phones deliver high quality photographs, which can help doctors make 
uncommon diagnoses
then blue with a burning pain (“pouring acid”), and 
finally a red phase combined with numbness as the pain 
decreased. The nipples would stay sore for some time 
afterwards. She presented three photographs from her 
camera phone depicting the colour changes of a typical 
episode (figure).
We suspected Raynaud’s phenomenon of the nipple 
because of the typical triphasic colour changes and simul-
taneous pain characteristics.
Beside sporadic episodes of migraine, the patient had 
no former medical history, no known nipple trauma, no 
breast surgery, no family history of collagen diseases, 
and she was a non-smoker. She had never before taken 
notice of the colour changes, although she had on some 
occasions experienced similar nipple pain since her late 
adolescence. These sporadic episodes had occurred only 
in winter when she had been skiing. Heat would typi-
cally resolve the symptoms. 
The intensity and frequency of the episodes increased 
dramatically during the patient’s pregnancy. Fresh epi-
sodes occurred whenever her fingers, toes, or nipples 
became cold, as when walking barefoot or taking a 
vasospasm of the arterioles manifesting as pallor (left), followed by cyanosis, and then erythema (centre). The right hand image 
shows the normal, asymptomatic, status
Raynaud’s phenomenon of the nipple is a possible diag-
nosis in lactating women with severe nipple pain. It is 
characterised by vasospasm of the arterioles causing 
intermittent ischaemia, which is manifested as pallor, fol-
lowed by cyanosis as the venous blood is deoxygenated, 
and then erythema when reflex vasodilatation occurs. 
Because symptoms do not appear straight after delivery, 
mothers may seek the help of their GPs rather than of 
hospital clinicians. It is important, therefore, to educate 
primary healthcare workers about severe nipple pain, 
especially since prompt recognition and treatment allow 
mothers to continue breastfeeding.
Case report
A 25 year old woman sought antenatal obstetric care 
early in the second trimester of her first pregnancy, 
reporting frequent episodes of extreme bilateral n ipple 
pain. A typical episode lasted between 5 and 15  minutes 
and was so painful as to bring her to tears.
She described how the pain altered in tandem with a 
triphasic colour change of the nipples: first white com-
bined with a tingling pain (“tightening a vice screw”), 
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shower. Their frequency increased from two to three 
episodes a week early in the second trimester to two to 
three episodes a day by the end of the third trimester. 
Symptom triggers were reduced, including minimised 
cold exposure (for example, wool bra pads and wool 
socks) and increased indoor temperature, with only a 
slight decrease in new episodes. In agreement with the 
patient, drug treatment was postponed until after she 
had given birth.
Surprisingly, the nipple pain resolved immediately 
after delivery (in gestational week 38, with birthweight 
at the lower end of normal at 2800 g), and she began 
breastfeeding during her stay on the labour ward with-
out pain. However, in the second week after delivery, 
the pain gradually returned during lactation with such 
intensity that breastfeeding became unbearable. It was 
most intense in the breast that produced the most milk. 
A lactation consultant confirmed correct positioning and 
latch. Nifedipine 30 mg sustained release tablet was then 
initiated, with symptoms completely resolving within 
one week. No side effects were registered.
We made two attempts at stopping the medication 6 
and 12 weeks postpartum. Both times the nipple pain 
returned during the following week with unbearable 
intensity, and the patient had to resort to using a breast 
pump. When nifedipine was reintroduced the pain 
resolved completely within a few days.
The treatment was successfully ceased one year post-
partum, and the patient experienced no further symp-
toms. The infant continued to be breastfed up to 18 
months and grew well. 
discussion
Nipple pain is a common cause of weaning, second only 
to low milk production.1 Poor positioning, or latch, is 
the most common cause of nipple pain.2 Blanching of 
the nipple may be caused by mechanical pressure. As 
in this patient, additional symptoms such as biphasic or 
triphasic colour changes, precipitation by cold stimulus, 
bilateral involvement, and occurrence of symptoms 
when the patient is not breastfeeding should therefore be 
present before a diagnosis of Raynaud’s phenomenon of 
the nipple is made. The severe pain combined with the 
whiteish changes of the nipple are often misinterpreted 
as candida, and many lactating women may be wrongly 
treated with repeated courses of antifungal therapy.3
Raynaud’s phenomenon in general occurs when the 
ambient temperature drops below a certain threshold 
that is specific to each individual.4 Exposure to cold 
should be avoided, and warm clothing and breastfeed-
ing in warm environments are encouraged. Patients with 
Raynaud’s phenomenon are usually advised to avoid 
medications or substances such as caffeine, nasal vaso-
constrictors, and tobacco that induce  vasoconstriction.4
Women with persistent pain require immediate relief 
to continue breastfeeding successfully. Recommended 
treatment is 30 mg nifedipine of sustained-release once-
daily formulation,4 and most women respond within two 
weeks.5 To our knowledge, all women described in the 
literature as having received medication experienced 
remission of symptoms and continued to  breastfeed 
their babies, although a second or third course was some-
times required.3 5 6 No adverse effects on the infants were 
reported, and the use of nifedipine during lactation is 
approved both by the British National Formulary7 and 
the American Academy of Pediatrics.8 The primary 
form of Raynaud’s phenomenon is related to functional 
alterations alone, being the most common form among 
women (85%).4 Secondary Raynaud’s phenomenon, 
which reflects structural microvascular abnormalities, has 
been associated with medical conditions such as connec-
tive tissue disease (for example, systemic sclerosis), drugs 
and toxic agents, and endocrine disorders (for example, 
hypothyroidism).
Increased activity of Raynaud’s phenomenon during 
pregnancy, as in this patient, is previously described in a 
patient with systemic sclerosis.9 Also in accordance with 
our case, Kahl et al showed that mean birth weight of 
babies of women with primary Raynaud’s phenomenon 
was reduced.10 This could represent a manifestation of 
systemic vasospasm.
Vasospasm of the nipple was first described in the 
1970s,11 although the association with Raynaud’s phe-
nomenon was first suggested by Coates et al in 1992.12 
Since then, only a limited number of case reports have 
been presented in the literature,3 5 6 12- 15 and the preva-
lence of the disease is unknown. The phenomenon is 
possibly an underdiagnosed cause of nipple pain. This 
could be because of GPs’ lack of awareness of it, espe-
cially when mothers seek the help of their GPs rather 
than of hospital clinicians due to delay of symptoms after 
delivery, and because symptoms of a single episode have 
vanished before the patient reaches the GP’s office.
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